Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486795 | 0.87 | EGFR (0.67) | EGFRERBB2KCNH2FLT1EPHA2 | |
| SCHEMBL4480617 | 0.86 | ERBB2 (0.78) | EGFRERBB2KCNH2 | |
| SCHEMBL4477566 | 0.86 | ERBB2 (0.78) | EGFRERBB2KCNH2 | |
| SCHEMBL3809898 | 0.85 | EGFR (0.66) | EGFRERBB2KCNH2FLT1EPHA2 | |
| SCHEMBL4464175 | 0.85 | ERBB2 (0.79) | EGFRERBB2KCNH2 | |
| SCHEMBL4480630 | 0.84 | EGFR (0.56) | EGFRERBB2KCNH2 | |
| SCHEMBL4491574 | 0.84 | EGFR (0.56) | EGFRERBB2KCNH2 | |
| SCHEMBL3811397 | 0.84 | ERBB2 (0.75) | EGFRERBB2KCNH2FLT1EPHA2 | |
| SCHEMBL3813145 | 0.84 | EGFR (0.65) | EGFRERBB2KCNH2FLT1EPHA2 | |
| SCHEMBL4478868 | 0.81 | ERBB2 (0.52) | EGFRERBB2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | EGFR 10/4885ERBB2 1/4885KCNH2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.